Zibotentan

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Zibotentan
Zibotentan.svg
Names
IUPAC name
N-(3-Methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide
Other names
ZD4054
Identifiers
CAS number 186497-07-4 YesY
ChemSpider 8085875
Jmol-3D images Image
PubChem 9910224
UNII 8054MM4902 YesY
Properties
C19H16N6O4S
Molar mass 424.43 g·mol−1
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 YesY verify (what isYesY/N?)
Infobox references

Zibotentan (INN) (earlier code name ZD4054) is an anti-cancer candidate.[1] It is an endothelin receptor antagonist.[2]

It failed a phase III clinical trial for prostate cancer[3] but other trials are planned.[4] Tolerability of zibotentan plus docetaxel has been evaluated.[5]

References[edit]

  1. ^ James and Growcott (2009). "Drugs of the Future". 
  2. ^ Tomkinson H, Kemp J, Oliver S, Swaisland H, Taboada M, Morris T (2011). "Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies". BMC Clin Pharmacol 11: 3. doi:10.1186/1472-6904-11-3. PMC 3070638. PMID 21414193. 
  3. ^ http://www.fiercebiotech.com/story/azs-zibotentan-flunks-late-stage-prostate-cancer-trial/2010-09-27
  4. ^ http://www.genengnews.com/gen-news-highlights/pfizer-astrazeneca-and-actelion-separately-report-phase-iii-trial-failures/81243985/
  5. ^ Trump DL, Payne H, Miller K, et al. (September 2011). "Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer". Prostate 71 (12): 1264–75. doi:10.1002/pros.21342. PMID 21271613. 

External links[edit]